Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00256685 |
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
Condition | Intervention | Phase |
---|---|---|
Menopause Hot Flashes Sleep Disorders |
Drug: DVS-233 SR |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Other inclusions apply.
Exclusion Criteria:
Other exclusions apply.
Study ID Numbers: | 3151A2-319 |
Study First Received: | November 17, 2005 |
Last Updated: | May 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00256685 |
Health Authority: | United States: Food and Drug Administration |
Menopause |
Signs and Symptoms Mental Disorders Hot Flashes |
Neurologic Manifestations Sleep Disorders Menopause |
Nervous System Diseases |